UroGen Pharma URGN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$133.23M+3.8% | -$153.49M-21.0% | -$164.64M-42.7% | -$154.97M-36.4% | -$138.43M-32.7% | ||
| $350K+2.9% | $347K-11.3% | $340K-33.7% | $340K-44.5% | $340K-52.3% | ||
| $13.52M+0.7% | $11.96M-8.8% | $12.13M-2.3% | $12.59M+12.9% | $13.42M+36.8% | ||
| —— | —— | —— | —— | —— | ||
| $13.33M+3,742% | $7.24M+104% | $747K-71.2% | -$314K-113% | $347K— | ||
| $5.02M— | $286K— | $6.49M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$685K-200% | -$202K-201% | -$1K— | $262K— | $683K— | ||
| $2.26M+114% | $2.1M+146% | $1.74M+104% | $1.38M+55.8% | $1.05M+15.4% | ||
| —— | —— | -$2.38M-181% | -$1.94M-109% | -$1.53M-55.3% | ||
| —— | —— | —— | —— | —— | ||
| -$165.74M-54.8% | -$162.44M-67.9% | -$137.74M-43.3% | -$123.13M-43.5% | -$107.06M-30.1% | ||
| $299K-11.8% | $289K-2.0% | $387K+64.0% | $396K+65.0% | $339K+98.2% | ||
| $102.96M-23.5% | $139.25M+29.3% | $180.94M+338% | $152.87M+278% | $134.62M+319% | ||
| $66.83M— | $61.56M— | —— | —— | —— | ||
| —— | —— | —— | —— | $18.37M+200% | ||
| $39.8M-58.8% | $39.8M-73.7% | $7.97M-94.7% | $15M-92.6% | $96.52M-20.9% | ||
| —— | $1.86M— | $1.39M— | $927.5K— | $463.75K— | ||
| $105.09M-24.9% | $39.92M-79.5% | $8.67M-95.5% | $40.01M-85.2% | $140M-18.1% | ||
| —— | —— | -$34.6M— | —— | —— | ||
| $1.08M-69.1% | $1.88M-35.1% | $3.14M+59.4% | $4.05M+354% | $3.48M+285% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$2.38M-181% | -$1.94M-109% | -$1.53M-55.3% | ||
| -$685K-200% | -$202K-201% | -$1K— | $262K— | $683K— | ||
| —— | —— | —— | —— | $2.49M+251% | ||
| $2.26M+114% | $2.1M+146% | $1.74M+104% | $1.38M+55.8% | $1.05M+15.4% | ||
| $102.96M-23.5% | $139.25M+29.3% | $180.94M+338% | $152.87M+278% | $134.62M+319% | ||
| —— | $1.86M— | $1.39M— | $927.5K— | $463.75K— | ||
| $5.81M-45.1% | $2.87M-81.0% | $7.66M-35.1% | $9.26M-19.2% | $10.59M-5.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$2.38M-181% | -$1.94M-109% | -$1.53M-55.3% | ||
| —— | $112K-81.2% | $233.25K-52.6% | $354.5K-8.3% | $475.75K+69.2% | ||
| —— | —— | —— | —— | $3.13M— | ||
| $5.44M+24.6% | $7.43M+220% | $9.18M— | $5.68M— | $4.37M— | ||
| —— | —— | —— | —— | $3.13M— | ||
| -$166.04M-54.6% | -$162.73M-67.7% | -$138.13M-43.3% | -$123.53M-43.6% | -$107.39M-30.2% | ||
| -$166.04M-54.6% | -$162.73M-67.7% | -$138.13M-43.3% | -$123.53M-43.6% | -$107.39M-30.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does UroGen Pharma generate?
- UroGen Pharma (URGN) generated -$165.7M in operating cash flow over the trailing twelve months.
- What is UroGen Pharma's free cash flow?
- After $299.0K of capital expenditures, UroGen Pharma's free cash flow was -$166.0M over the trailing twelve months, down 54.6% year over year.
- Where does UroGen Pharma's cash flow data come from?
- Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
